The Fort Worth Press - Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

USD -
AED 3.672498
AFN 64.999798
ALL 82.324126
AMD 360.439737
ANG 1.790403
AOA 917.999825
ARS 1543.774978
AUD 1.480635
AWG 1.8
AZN 1.699363
BAM 1.774194
BBD 2.019595
BDT 124.714249
BGN 1.77347
BHD 0.378283
BIF 3011.049223
BMD 1
BND 1.291133
BOB 11.706702
BRL 5.686902
BSD 1.002676
BTN 94.445982
BWP 14.014686
BYN 3.004037
BYR 19600
BZD 2.016692
CAD 1.42842
CDF 2315.00023
CHF 0.840095
CLF 0.025417
CLP 1000.480332
CNY 6.67175
CNH 6.66782
COP 3316.61
CRC 449.312832
CUC 1
CUP 24.064734
CVE 100.026761
CZK 22.18975
DJF 178.554905
DKK 6.790305
DOP 60.996961
DZD 137.014347
EGP 53.649023
ERN 15
ETB 164.576405
EUR 0.90831
FJD 2.280098
FKP 0.756558
GBP 0.75785
GEL 2.590074
GGP 0.756558
GHS 11.756648
GIP 0.756558
GMD 74.000006
GNF 8883.828946
GTQ 7.665407
GYD 209.778157
HKD 7.84665
HNL 26.963428
HRK 6.831965
HTG 131.493006
HUF 331.23032
IDR 18267.95
ILS 3.22225
IMP 0.756558
INR 93.92255
IQD 1520.102326
IRR 1913737.523681
ISK 124.069717
JEP 0.756558
JMD 158.434973
JOD 0.70902
JPY 159.523499
KES 130.039569
KGS 87.449397
KHR 4119.418691
KMF 447.000366
KPW 900.00035
KRW 1335.070061
KWD 0.31151
KYD 0.835571
KZT 446.941108
LAK 22570.768945
LBP 89792.715562
LKR 333.502667
LRD 170.460782
LSL 16.951345
LTL 2.95274
LVL 0.60489
LYD 6.463464
MAD 9.936772
MDL 18.213733
MGA 4555.721867
MKD 55.90096
MMK 2099.568705
MNT 3604.028735
MOP 8.103614
MRU 40.552456
MUR 47.809885
MVR 15.396662
MWK 1738.739965
MXN 18.573803
MYR 4.093898
MZN 63.899938
NAD 16.951268
NGN 1347.489819
NIO 36.903315
NOK 9.600095
NPR 151.114437
NZD 1.81263
OMR 0.384508
PAB 1.002667
PEN 3.411771
PGK 4.5757
PHP 63.963967
PKR 277.274459
PLN 4.00014
PYG 6223.068898
QAR 3.655265
RON 4.859302
RSD 106.818993
RUB 82.553706
RWF 1483.473867
SAR 3.763142
SBD 8.097697
SCR 13.770647
SDG 601.516238
SEK 10.079445
SGD 1.2891
SHP 0.752984
SLE 23.050274
SLL 20969.503664
SOS 573.051087
SRD 37.49018
STD 20697.981008
STN 22.225347
SVC 8.773903
SYP 13002.000337
SZL 16.945524
THB 33.901027
TJS 9.24984
TMT 3.5
TND 3.022529
TOP 2.40776
TRY 50.392297
TTD 6.806306
TWD 32.943501
TZS 2651.477006
UAH 45.588969
UGX 4141.134208
UYU 40.639897
UZS 12057.766973
VES 912.87925
VND 25764
VUV 120.719595
WST 2.810584
XAF 595.812425
XAG 0.021002
XAU 0.000258521515
XCD 2.70255
XCG 1.807123
XDR 0.707052
XOF 595.812425
XPF 108.186074
YER 236.549829
ZAR 16.951101
ZMK 9001.197322
ZMW 20.500748
ZWL 321.999592
SSP 5945.381189
MXV 2.084233
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

MIAMI, FLORIDA / ACCESS Newswire / February 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or Telomir, a leader in age-reversal science, today announced groundbreaking results from its recent preclinical studies conducted in human retinal cell lines. These studies demonstrated the ability of Telomir-1 to significantly reverse copper and iron-induced elevation of Reactive Oxygen Species (ROS).

Text size:

Age-Related Macular Degeneration (AMD) and Current Treatment Challenges

AMD is a leading cause of blindness in adults over 50, affecting millions worldwide. The disease is characterized by the progressive deterioration of the retinal pigment epithelium (RPE) and photoreceptor cells, leading to central vision loss. AMD is classified into two forms:

  • Dry (atrophic) AMD, the most common form, which is characterized by a gradual loss of RPE and photoreceptors due to oxidative stress and inflammation.

  • Wet (neovascular) AMD, a more severe form, where abnormal blood vessel growth causes rapid and severe vision loss.

Current treatments primarily aim to slow the progression of AMD rather than reverse the damage. Anti-VEGF injections, the standard for wet AMD, can reduce vision loss but require frequent and costly treatments with potential risks such as retinal detachment and infection. The AREDS2 formula, an antioxidant supplement, offers modest benefits in delaying intermediate AMD but does not restore lost vision. Laser and photodynamic therapies, once widely used, are now less common due to risks of retinal scarring and limited long-term efficacy. While gene and stem cell therapies are emerging, no FDA-approved treatments directly target oxidative stress, a key factor in AMD progression.

Despite these treatments, there remains an urgent need for therapies that address the root causes of AMD, particularly oxidative stress and metal-induced toxicity, which drive retinal degeneration. Telomir-1 represents a novel approach by targeting these underlying mechanisms, offering a potential disease-modifying solution rather than just slowing its effects.

"The continued success of Telomir-1 in regulating oxidative stress is further proof of its potential to transform healthcare and redefine how we approach aging and age-related diseases," said Erez Aminov, Chairman & CEO of Telomir. "Rather than merely addressing symptoms, our focus is on targeting the root causes of disease at the cellular level. Telomir-1's ability to mitigate oxidative damage underscores its promise as a breakthrough therapy, not only for AMD but for a broader range of age-related conditions."

Telomir-1: A Novel Approach to Combating Oxidative Stress in AMD

Telomir's lead compound, Telomir-1, was developed to neutralize metal-induced oxidative stress-a key driver of AMD progression. In a recently conducted preclinical study using human retinal cell lines, Telomir-1 demonstrated the ability to significantly reduce ROS levels, thereby reversing oxidative damage, suggesting therapeutic potential in AMD and other retinal diseases.

Key Study Findings:

  • Copper and iron exposure significantly increased ROS levels in human retinal cells, accelerating oxidative stress and cellular damage.

  • Telomir-1 treatment resulted in a significant reduction of copper and iron-induced ROS elevation, mitigating oxidative stress at the cellular level.

  • Telomir-1 exhibited strong ROS reduction properties at low concentrations, suggesting regulatory, rather than chelation properties, and a high therapeutic potential for AMD.

  • The ability to reduce oxidative stress may have implications beyond AMD, potentially benefiting other retinal diseases linked to oxidative damage.

"Our findings reinforce the crucial role of metal ions and oxidative stress in AMD and suggest that Telomir-1 could provide a breakthrough approach to protecting retinal cells from degeneration," said Dr. Angel, Chief Scientific Advisor at Telomir. "Unlike current AMD treatments that primarily manage symptoms, Telomir-1 directly targets oxidative stress and metal-induced toxicity, key factors in disease progression."

Next Steps in Telomir-1 Development

Telomir has planned AMD disease models to further evaluate the efficacy of Telomir-1 in vivo. These studies will explore how Telomir-1 can protect against progressive retinal degeneration and vision loss, paving the way for potential clinical development.

In addition to AMD, Telomir will be conducting studies to evaluate the potential of Telomir-1 in Wilson's disease, progeria, cancer, Alzheimer's, and other age-related conditions. Furthermore, research will be expanded into infectious diseases, including influenza and bird flu, to assess how Telomir-1's metal ion regulation capabilities may impact viral pathogenesis and immune response.

About Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule metal ion regulator designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1, starting with ongoing research in animals and then in humans.

Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life.

Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing.

Cautionary Note Regarding Forward-Looking Statements

This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Contact Information

Helga Moya
[email protected]
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc



View the original press release on ACCESS Newswire

X.Silva--TFWP